Skip to main content
. Author manuscript; available in PMC: 2017 Sep 28.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2011 Aug 10;22(2):100–106. doi: 10.1016/j.jstrokecerebrovasdis.2011.06.017

Table 4.

Association between aspirin treatment failure and endpoints according to stroke subtype: Analysis of data from the NINDS intravenous recombinant tissue plasminogen trial

Event rate Univariate analysis Multivariate analysis
Patients taking aspirin before ischemic stroke Patients not taking aspirin before ischemic stroke P value OR (95% CI) P value
Stroke within 1 year
 Large vessel disease 1/36 (3%) 4/89 (4%) 1 0.64 (0.7–6.0) .69
 Cardioembolic 8/91 (9%) 12/150 (8%) .81 1.1 (0.43–2.8) .86
 Small vessel disease 0/23 (0%) 1/38 (3%) —* —* —*
Stroke or death within 1 year
 Large vessel disease 8 (22%) 28 (31%) .38 0.57 (0.22–1.5) .24
 Cardioembolic 34 (37%) 60 (30%) .79 0.97 (0.54–1.7) .91
 Small vessel disease 1 (4%) 5 (13%) .39 —* —*

Abbreviations: CI, confidence interval; NINDS, National Institute of Neurological Disorders and Stroke; OR, odds ratio.

*

Analysis not possible.